ArticleHepatology communications2026
Prospective comparative assessment of liver stiffness and steatosis between iLivTouch and FibroScan.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease currently represents the leading cause of chronic liver disease worldwide. FibroScan and iLivTouch are 2 devices that employ similar principles to estimate liver steatosis and fibrosis, although few studies have directly compared their results.
aimTo evaluate the concordance of 2 transient elastography devices for the estimation of liver steatosis and fibrosis.
methodsA prospective study was conducted. Each participant underwent liver elastography with both devices consecutively under standardized conditions. Clinical, anthropometric, and biochemical variables were collected. The diagnostic accuracy of iLivTouch was calculated using FibroScan and noninvasive scores as references.
resultsA total of 1004 patients were enrolled, with a median body mass index of 25.7 kg/m2 [IQR=23.6-28.7]. Median of attenuation values was 250 dB/m [IQR=214-291] with FibroScan, 262 dB/m [IQR=239-310] with iLivTouch. Median liver stiffness measurements were 4.1 kPa [IQR=3.4-4.8] for FibroScan and 6.2 kPa [IQR=5.5-7.1] for iLivTouch. Bland-Altman analysis revealed mean differences of -19.45±49.62 dB/m for steatosis and -2.43±2.51 kPa for stiffness. Using FibroScan (>269 dB/m) as the reference, iLivTouch ≥244 dB/m demonstrated 90% sensitivity for detecting liver steatosis. The correlation between the FAST scores of the 2 devices was very strong (rho=0.90, p≤0.0001).
conclusioniLivTouch serves as an effective alternative to assess liver fibrosis and steatosis in the general population, including overweight and obese individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.